Soluble PD-1, PD-L1 and BTLA as prognostic biomarkers in patients with pancreatic adenocarcinoma

The present invention relates to a prognostic method of pancreatic cancer. In the present study, the inventors use specific antibodies to monitor the concentrations of soluble forms of PD-1 and PD-L1 and BTLA in plasma of advanced PDAC patients, which are not eligible for resection, by ad hoc developed ELISAs. They showed that high plasma levels of these immune checkpoints correlate with poor outcome and can be used as prognostic factors in non-resectable PDAC. Thus the present invention relates to a method for predicting the survival time of a patient suffering from a pancreatic cancer comprising determining in a sample obtained from the patient the expression level of PD-1 and/or PD-L1.

Scientific publication(s):
Oncoimmunologn, 2019 Feb 3, Bian B. et al., Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma, doi: 10.1080/2162402X.2018.1561120

Keywords : ELISA, Immunoassay, Prognosis in Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, PDAC
Patent Application number : EP18 306 440.1
EP18 306 439.3
Patent Application date : 2018-11-02
Multidisciplinary field : -
Technology/Engineering : -
Technological Platform : Immunoassay
Rare disease : -
Second indication : -
Inventors : Jean-Charles DAGORN
Daniel OLIVE
Juan-Lucio IOVANNA
Publications :
  • Oncoimmunology. 2019 Feb 3;8(4):e1561120. doi: 10.1080/2162402X.2018.1561120. eCollection 2019.

Related offers

The 10 Last viewed

You haven't seen any form yet.